Salvianolic acid B functioned as a competitive inhibitor of matrix metalloproteinase-9 and efficiently prevented cardiac remodeling

BMC Pharmacology

Volumn 10, Issue , 2010, Pages

  Jiang, Baohong ^a   Chen, Jing ^a   Xu, Lingling ^a   Gao, Zhenting ^b   Deng, Yanping ^a   Wang, Yanhui ^a,c   Xu, Feng ^c   Shen, Xu ^a   Guo, De An ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^b EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE B; SALVIANOLIC ACID B; BENZOFURAN DERIVATIVE; GELATINASE A; HERBACEOUS AGENT; HYBRID PROTEIN; MMP2 PROTEIN, RAT; PROTEINASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CATALYSIS; DRUG PROTEIN BINDING; ECHOCARDIOGRAPHY; ENZYME ACTIVITY; ENZYME INHIBITION; HEART DISEASE; HEART INFARCTION; HEART LEFT VENTRICULAR REMODELLING; HEART MUSCLE CONTRACTILITY; HEART MUSCLE FIBROSIS; HEART OUTPUT; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; HEMODYNAMICS; HISTOPATHOLOGY; MALE; MOLECULAR DOCKING; NONHUMAN; PROTEIN EXPRESSION; RAT; WESTERN BLOTTING; ZYMOGRAPHY; ANIMAL; BINDING SITE; CHEMISTRY; COMPUTER SIMULATION; CONFORMATION; DOWN REGULATION; DRUG ANTAGONISM; DRUG DESIGN; DRUG EFFECT; FIBROSIS; GENETICS; HEART CONTRACTION; HEART VENTRICLE; HEART VENTRICLE REMODELING; HUMAN; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; RANDOMIZATION; WISTAR RAT;

ANIMALS; BENZOFURANS; BINDING SITES; COMPUTER SIMULATION; DOWN-REGULATION; DRUG DESIGN; DRUGS, CHINESE HERBAL; FIBROSIS; HEART VENTRICLES; HUMANS; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MOLECULAR CONFORMATION; MYOCARDIAL CONTRACTION; MYOCARDIAL INFARCTION; PROTEASE INHIBITORS; RANDOM ALLOCATION; RATS; RATS, WISTAR; RECOMBINANT FUSION PROTEINS; VENTRICULAR REMODELING;

EID: 77955793354     PISSN: None     EISSN: 14712210     Source Type: Journal    
DOI: 10.1186/1471-2210-10-10     Document Type: Article

References (26)

1. Fang J, Alderman MH. Dissociation of hospitalization and mortality trends for myocardial infarction in the United States from 1988 to 1997. AM J Med 2002, 113:208-214. 10.1016/S0002-9343(02)01172-5, 12208379.
2. Yousef ZR, Redwood SR, Marber MS. Postinfarction left ventricular remodeling: A pathophysiological and therapeutic review. Cardiovasc Drugs Ther 2002, 14:243-252.
3. Spinale FG. Matrix metalloproteinases: regulation and dysregulation in the failing heart. Circ Res 2002, 90:520-530. 10.1161/01.RES.0000013290.12884.A3, 11909815.
4. Gallagher GL, Jackson CJ, Hunyor SN. Myocardial extracellular matrix remodeling in ischemic heart failure. Front Biosci 2007, 12:1410-1419. 10.2741/2157, 17127391.
5. Frangogiannis NG, Smith CW, Entman ML. The inflammatory response in myocardial infarction. Cardiovasc Res 2002, 53:31-47. 10.1016/S0008-6363(01)00434-5, 11744011.
6. Romanic AM, Harrison SM, Bao W, Burns-Kurtis CL, Pickering S, Gu J, Grau E, Mao J, Sathe GM, Ohlstein EH, Yue TL. Myocardial protection from ischemia/reperfusion injury by targeted deletion of matrix metalloproteinase-9. Cardiovasc Res 2002, 54:549-558. 10.1016/S0008-6363(02)00254-7, 12031700.
7. Moshal KS, Rodriguez WE, Sen U, Tyagi SC. Targeted deletion of MMP-9 attenuates myocardial contractile dysfunction in heart failure. Physiol Res 2008, 57:379-384.
8. Ikonomidis JS, Barbour JR, Amani Z, Stroud RE, Herron AR, McClister DM, Camens SE, Lindsey ML, Mukherjee R, Spinale FG. Effects of deletion of the matrix metalloproteinase 9 gene on development of murine thoracic aortic aneurysms. Circulation 2005, 112:1242-1248. 10.1161/CIRCULATIONAHA.104.532259, 16129808.
9. Lindsey ML, Escobar GP, Dobrucki LW, Goshorn DK, Bouges S, Mingoia JT, McClister DM, Su H, Gannon J, MacGillivray C, Lee RT, Sinusas AJ, Spinale FG. Matrix metalloproteinase-9 gene deletion facilitates angiogenesis after myocardial infarction. Am J Physiol Heart Circ Physiol 2006, 290:H232-H239. 10.1152/ajpheart.00457.2005, 16126817.
10. Heymans S, Lupu F, Terclavers S, Vanwetswinkel B, Herbert JM, Baker A, Collen D, Carmeliet P, Moons L. Loss or inhibition of uPA or MMP-9 attenuates LV remodeling and dysfunction after acute pressure overload in mice. Am J Pathol 2005, 166:15-25. 1602291, 15631996.
11. Han JY, Fan JY, Horie Y, Miura S, Cui DH, Ishii H, Hibi T, Tsuneki H, Kimura I. Ameliorating effects of compounds derived from Salvia miltiorrhiza root extract on microcirculatory disturbance and target organ injury by ischemia and reperfusion. Pharmacol Ther 2008, 117:280-295. 10.1016/j.pharmthera.2007.09.008, 18048101.
12. Jiang B, Wu W, Li M, Xu L, Sun K, Yang M, Guan S, Liu X, Guo DA. Cardioprotection and matrix metalloproteinase-9 regulation of salvianolic acids on myocardial infarction in rats. Planta Med 2009, 75:1286-1292. 10.1055/s-0029-1185669, 19431100.
13. Shipley JM, Doyle GA, Fliszar CJ, Ye QZ, Johnson LL, Shapiro SD, Welgus HG, Senior RM. The structural basis for the elastolytic activity of the 92-kDa and 72-kDa gelatinases. Role of the fibronectin type II-like repeats. J Biol Chem 1996, 271:4335-4341. 10.1074/jbc.271.8.4335, 8626782.
14. Mukherjee R, Mingoia JT, Bruce JA, Austin JS, Stroud RE, Escobar GP, McClister DM. Selective spatiotemporal induction of matrix metalloproteinase-2 and matrix metalloproteinase-9 transcription after myocardial infarction. Am J Physiol Heart Circ Physiol 2006, 291:H2216-H2228. 10.1152/ajpheart.01343.2005, 16766634.
15. Zao ZY, Cavasin MA, Yang F, Liu YH, Yang XP. Temporal changes in matrix metalloproteinase expression and inflammatory response associated with cardiac rupture after myocardial infarction in mice. Life Sci 2004, 74:1561-1572. 10.1016/j.lfs.2003.09.042, 14729404.
16. Xu M, Guo H, Han J, Sun SF, Liu AH, Wang BR, Ma XC, Liu P, Qiao X, Zhang ZC, Guo DA. Structural characterization of metabolites of salvianolic acid B from Salvia miltiorrhiza in normal and antibiotic-treated rats by liquid chromatography-mass spectrometry. J Chromatogr B 2007, 858:184-198.
17. Radauceanu A, Ducki C, Virion JM, Rossignol P, Mallat Z, McMurray J, Van Veldhuisen DJ, Tavazzi L, Mann DL. Capiaumont-Vin J, Li M, Hanriot D, Zannad F. Extracellular matrix turnover and inflammatory markers independently predict functional status and outcome in chronic heart failure. J Card Fail 2008, 14:467-474. 10.1016/j.cardfail.2008.02.014, 18672194.
18. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 2003, 92:827-39. 10.1161/01.RES.0000070112.80711.3D, 12730128.
19. Maskos K. Crystal structures of MMPs in complex with physiological and pharmacological inhibitors. Biochimie 2005, 87:249-263. 10.1016/j.biochi.2004.11.019, 15781312.
20. Rowsell S, Hawtin P, Minshull CA, Jepson H, Brockbank SM, Barratt DG, Slater AM, McPheat WL, Waterson D, Henney AM, Pauptit RA. Crystal structure of human MMP-9 in complex with a reverse hydroxamate inhibitor. J Mol Biol 2002, 319:173-181. 10.1016/S0022-2836(02)00262-0, 12051944.
21. Kiyama R, Tamura Y, Watanabe F, Tsuzuki H, Ohtani M, Yodo M. Homology modeling of gelatinase catalytic domains and docking simulations of novel sulfonamide inhibitors. J Med Chem 1999, 42:1723-1738. 10.1021/jm980514x, 10346925.
22. Cuniasse P, Devel L, Makaritis A, Beau F, Georgiadis D, Matziari M, Yiotakis A, Dive V. Future challenges facing the development of specific active-site-directed synthetic inhibitors of MMPs. Biochimie 2005, 87:393-402. 10.1016/j.biochi.2004.09.025, 15781327.
23. Tochowicz A, Maskos K, Huber R, Oltenfreiter R, Dive V, Yiotakis A, Zanda M, Pourmotabbed T, Bode W, Goettig P. Crystal structures of MMP-9 complexes with five inhibitors: contribution of the flexible Arg424 side-chain to selectivity. J Mol Biol 2007, 371:989-1006. 10.1016/j.jmb.2007.05.068, 17599356.
24. Kaludercic N, Lindsey ML, Tavazzi B, Lazzarino G, Paolocci N. Inhibiting metalloproteases with PD166793 in heart failure: impact on cardiac remodeling and beyond. Cardiovasc Ther 2008, 26:24-37.
25. Overall CM, Lopez-Otin C. Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat Rev Cancer 2002, 2:657-672. 10.1038/nrc884, 12209155.
26. Adams JD, Wang R, Yang J, Lien EJ. Preclinical and clinical examinations of Salvia miltiorrhiza and its tanshinones in ischemic conditions. Chin Med 2006, 1:3. 10.1186/1749-8546-1-3, 1761145, 17302964.